Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma

Asthma Chronic Clinical Trial

Official title:

Evaluation of the Efficacy and Mechanism of Action of Huang-long Zhi-xiao Granule to Improve the Control Rate of Chronic Persistent of Asthma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05841901
• Other study ID #: TCM for Asthma
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 1, 2023
• Est. completion date: December 1, 2024

Study information

• Verified date: April 2023
• Source: Henan University of Traditional Chinese Medicine
• Contact: Minghang Wang, MD
• Phone: 0371-66248624
• Email: wmh107hn[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this observational study is to test the Evaluation of the efficacy and mechanism of action about Huang-long Zhi-xiao Granule to improve the control rate of Asthma chronic duration. The main questions it aims to answer are:

• [Relying on the top-level experimental design, scientifically evaluated the efficacy and safety of Huang-long Zhi-xiao Granule in patients with chronic asthma (hot asthma), and provided evidence support for the clinical application of Classical Prescriptions.]

• [Through the retained sample to test Asthma-related inflammatory indicators, immunoglobulins, T cell subsets, etc. To investigate the mechanism of action of Huang-long Zhi-xiao Granule in patients with chronic duration of asthma (hot asthma).]

Description:

Bronchial asthma attacks are erratic and difficult to heal, which seriously affects the quality of life of patients, and their physical and mental health is also seriously affected by asthma.

This study will conduct clinical observations in patients with chronic persistence (hot wheezing) of bronchial asthma, scientifically evaluate the efficacy and safety of Huanglong Anti-Wheezing in patients with asthma chronic duration (hot wheezing), and provide evidence support for the clinical application of Huanglong Anti-Wheezing Formula.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 224
• Est. completion date: December 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients who meet the diagnostic criteria for chronic persistent bronchial asthma

• It meets the TCM differentiation standards for wheezing and hot wheezing

• Asthma Control Test (ACT) questionnaire score<20 score

• The severity of disease is graded from mild to moderately persistent

• Patients who have not been treated with anti-asthmatic drugs for 2 weeks prior to dosing or who have been treated with ICS or ICS+LABA for 4 weeks or more prior to dosing and who have the same type and dose of the drug

• Age form 18-80 years old

• Have not participated in other clinical studies within 1 month prior to enrollment

• Voluntarily participate in the study and sign an informed consent form

Exclusion Criteria:

• Patients with special types of refractory asthma, critical asthma, occupational asthma, seasonal asthma, atypical asthma or tuberculosis, pulmonary interstitial fibrosis, thoracic malformation, chronic obstructive pulmonary disease, bronchiectasis, cystic pulmonary fibrosis, allergic bronchopulmonary aspergillosis, allergic granulomatous vasculitis, infectious, restrictive lung disease and other airflow obstructive pulmonary diseases

• Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina, acute myocardial infarction, cardiac function grade 3 and above, stroke, cerebral hemorrhage, etc.)

• Glutamate aminotransferase (ALT), aspartate aminotransferase (AST) > 1.5 times the upper limit of normal value, blood creatinine (Cr) > upper limit of normal value

• Those who are allergic and allergic to the components of drugs in known test drugs

• Patients with bronchiectasis, tuberculosis, pulmonary embolism, or other serious respiratory conditions

• Combined with severe cognitive and psychiatric abnormalities

• Participants who are pregnant, lactating, and planning to become pregnant

• Those who are participating in other clinical trials within 1 month prior to enrollment

Related Conditions & MeSH terms

• Asthma
• Asthma Chronic

Intervention

Drug:
• Huang-long Zhi-xiao Granule
The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
• Huang-long Zhi-xiao Granule placebo
The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Henan University of Traditional Chinese Medicine	The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, The Third Affiliated Hospital of Henan University of Traditional Chinese Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asthma control tests(CAT)	CAT will be used to evaluate quality of life. A total score of 0-40 will be given with a higher score indicating a worse condition.	Change from baseline CAT scores at week 4, 8, 21, 34,47 and 52.
Primary	Frequencies of acute attacks	It will be assessed by frequencies of asthma-related hospitalizations.The patient's disease progression was recorded by recording the number of acute attacks at each time point, as well as the specific condition at the time of the attack.	Up to week 52.
Secondary	Asthma exacerbation severity and hospitalization rate	Worsening lung function during asthma attacks is characterized by decreased expiratory flow, and the severity of the exacerbation can be graded by the patient's symptoms, lung function, and arterial blood gas analysis.According to the frequency of daytime and nighttime asthma attacks and pulmonary function test results, the patients were divided into 4 grades, namely: 1 intermittent attack; 2 mild persistent; 3 moderate persistent and 4 severe persistent.The severity of the asthma attack was assessed using a rating scale	Week0(before treatment),week4?week8?week21?week34?week47and week52.
Secondary	Change in severity of chronic persistent disease	Although the patient does not have an acute attack of asthma, there are still symptoms such as wheezing, cough, chest tightness and other symptoms with different frequency and degrees for a long time, which may be accompanied by decreased pulmonary ventilation function. The severity of chronic persistent asthma can be classified into four levels: intermittent, mildly persistent, moderately persistent, and severely persistent, according to the frequency of daytime and nighttime asthma symptoms and the results of pulmonary function tests.The severity of the asthma attack was assessed using a rating scale	Week0(before treatment),week4?week8?week21?week34?week47and week52.
Secondary	The dose used by glucocorticoids	Corticosteroids are the drug of choice for long-term asthma treatment. The vast majority of patients with chronic persistent asthma are well controlled by inhaling low-dose corticosteroids (equivalent to 400 micrograms of budesonide per day).	Week0(before treatment),week4?week8?week21?week34?week47 and week52.
Secondary	Rapid-acting beta2 agonists use drugs and doses	Beta2 agonists are asthma drugs that stimulate beta2 receptors distributed on airway smooth muscle to produce bronchodilating effects. These drugs are bronchodilators and are the drugs of choice for acute asthma attacks (airway spasm), which can quickly improve symptoms such as dyspnea, cough, etc. If given by inhalation, salbutamol 100-200mcg or terbutaline 250-500mcg at a time and repeat every 20 minutes if necessary,	Week0(before treatment),week8 and after follow-up(week52)
Secondary	Score for clinical signs and symptoms	Formulate with reference to the "Guidelines for Clinical Research of New Chinese Medicines"Clinical scoring is weighted or assigned according to some of the main symptoms, signs, physiological parameters of patients, etc., so as to quantitatively evaluate the severity of the disease.The higher the score, the worse the state.	Week0(before treatment),week8 and after follow-up(week52)
Secondary	Pulmonary function	Pulmonary function tests are an important part of the assessment of asthma and use objective indicators of lung function to monitor asthma.Routine pulmonary ventilation tests should be performed in all patients with clinically suspected asthma, and bronchodilator tests may be performed if ventilatory function suggests an obstructive change in ventilation. If the diastolic test is positive, the diagnosis of asthma can be established combined with clinical history, if the diastolic test is negative and FEV1 & GT. 70% predicted value, the conditional unit can do bronchial provocation test.	Week0(before treatment),week4?week8?week21?week34?week47and week52.
Secondary	Exhaled nitric oxide		Week0(before treatment),week4?week8?week21?week34?week47and week52.
Secondary	Asthma Control Questionnaire (ACQ)	The content of ACQ involves the following aspects: asthma-related, symptoms, the use of first-aid drugs, the impact on daily life and lung function test results.The higher the score, the worse the state.	Week0(before treatment),week8 and after follow-up(week52)
Secondary	Asthma Quality of Life Score (AQLQ) score	The asthma quality of life scale (5-point scale-RRB- consists of 35 items, including activity limitation (1-12) , asthma symptoms (13-20) , psychological status (22-26) , response to stimuli (27-31) , concern for one's own health (32-35) . On a 5-point scale, 1 is the worst and 5 is the best.	Week0(before treatment),week8 and after follow-up(week52)
Secondary	Sputum detection indicators	?Induced sputum inflammatory phenotype: the inflammatory phenotype was classified into eosinophilic asthma, neutrophil asthma, paucigranulocytic asthma and mixed granulocytic asthma according to the detection of Eos in sputum?Eosinophil granulocyte cationic protein(EPC)?Inflammatory factors: IL-4, IL-5, Il-13, IL-25?Mucin MUC5AC.	Week0(before treatment), week 8,after follow-up(week52)